Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours

NCT01861496 is registered in ClinicalTrials.gov with Allarity Therapeutics as lead sponsor.

NCT NCT01861496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01861496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours
Lead sponsor
Allarity Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2013
Completion date
October 31, 2021
Enrollment
50 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

phase 1: advanced or refractory solid tumours, phase 2 part: metastatic breast cancer, prostate cancer and skin cancer